Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07203898 | A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 1 | 36 | Beijing Immupeutics Medicine Technology LimitedINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT07201571 | A Retrospective Cohort Study of Patients Who Underwent Curative-intent Esophagectomy for ESCC at a Tertiary Referral Center in South Korea | completed | — | 3,131 | Samsung Medical CenterOTHER | 0 | Oct 1, 2025 |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT06333665 | PPIO-007 Correlation Analysis of Type II Diabetes Mellitus on Short-term and Long-term Outcomes of Patients With Esophageal Squamous Cell Cancer Undergoing Minimally Invasive Esophagectomy | completed | — | 605 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05022654 | SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | active not recruiting | Phase 2 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06008054 | A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors | recruiting | Phase 2 | 376 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07104838 | Non-intubated Versus Intubated Anesthesia in Thoracoscopic Esophagectomy for Esophageal Cancer | not yet recruiting | N/A | 500 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 25, 2025 | clinicaltrials |
| NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 37 | Anhui Provincial HospitalOTHER_GOV | 1 | Sep 23, 2025 | clinicaltrials |
| NCT00900419 | Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers | recruiting | — | 700 | University of Colorado, DenverOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT07182266 | Perioperative Outcomes and Survival of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy for Selected Esophageal Cancer | completed | — | 1,661 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06500052 | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors | recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07180134 | Health Informatics and Resistance Exercise for Symptom Management and Quality of Life in Post-Esophagectomy Patients | not yet recruiting | N/A | 90 | Chang Gung Memorial HospitalOTHER | 0 | Sep 18, 2025 | clinicaltrials |
| NCT07181850 | Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features(pCR-ESCC) | completed | — | 363 | Nanjing Medical UniversityOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04892849 | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy(ST-ICI02) | recruiting | — | 200 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04938973 | NIF-Guided RAMIE Using ICG Versus OTE Feasibility RCT(RAMIE vs OTE) | terminated | N/A | 24 | St. Joseph's Healthcare HamiltonOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT06601309 | Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC(ESCC) | recruiting | Phase 2 | 90 | Fujian Medical University Union HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07124351 | Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) | recruiting | Phase 4 | 15 | Cedars-Sinai Medical CenterOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT03110926 | Induction Chemotherapy for Locally Advanced Esophageal Cancer | active not recruiting | Phase 2 | 40 | University of RochesterOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06796764 | COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial | recruiting | N/A | 580 | Zhejiang UniversityOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07164690 | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy | not yet recruiting | Phase 2 | 32 | Fudan UniversityOTHER | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07165184 | Incidence of 107 Lymph Node Metastasis | recruiting | — | 1,100 | Fudan UniversityOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07165210 | Incidence of 106TBL Lymph Node Metastasis | recruiting | — | 1,852 | Fudan UniversityOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT00924027 | A Study of Patients Receiving High-Dose Rate Brachytherapy | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07154108 | Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer | not yet recruiting | Phase 1 | 40 | Sichuan UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02415101 | Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer(NeoResII) | completed | N/A | 202 | Karolinska University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06247956 | Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer | active not recruiting | Phase 2 | 153 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07152535 | Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor(PKU-ESCC) | not yet recruiting | — | 255 | Peking University Cancer Hospital & InstituteOTHER | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07152678 | Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in Esophageal Squamous Cell Carcinoma(BRIGHT-ESCC) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06509568 | Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） | recruiting | Phase 2 | 92 | Zhejiang Cancer HospitalOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT06420908 | Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2025 | clinicaltrials |
| NCT07142421 | A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT05880082 | PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer(PPIO-004-EC001) | completed | Phase 2 | 118 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT07128693 | A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07114627 | Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients(ESCAPE) | recruiting | — | 66 | Erasmus Medical CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT07112833 | A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) | not yet recruiting | Phase 2 | 36 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT06275165 | The Effects of Acupressure on Improving Postoperative Gastrointestinal Symptom Distress in Esophageal Cancer Patients | completed | N/A | 48 | CHEN, CHIA-CHENOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108855 | Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection(BRIGHT) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 7 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT02534233 | Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium(ColdPlay2) | completed | N/A | 58 | Johns Hopkins UniversityOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07022886 | INCIDENCE, PREVALENCE AND OVERALL RISK OF ESOPHAGEAL CANCER IN ACHALASIA: A PROPENSITY-MATCHED POPULATION-BASED STUDY FROM A LARGE MULTICENTER DATABASE(RECAP) | active not recruiting | — | 47,000 | IRCCS San RaffaeleOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT03161535 | Effectiveness of a Rehabilitation Program in Improving Quality of Life in Patients With Esophageal Cancer | active not recruiting | N/A | 85 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088354 | Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy(DL-ESCC) | recruiting | — | 300 | Tongji HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2025source: clinicaltrials